3C protease of enterovirus 71 cleaves promyelocytic leukemia protein and impairs PML-NBs production.
3C protease
Cleavage
Enterovirus 71 (EV71)
PML nuclear bodies (PML-NBs)
Promyelocytic leukemia (PML)
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
received:
16
09
2021
accepted:
08
12
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
12
3
2022
Statut:
epublish
Résumé
Enterovirus 71 (EV71) usually infects infants causing hand-foot-mouth disease (HFMD), even fatal neurological disease like aseptic meningitis. Effective drug for preventing and treating EV71 infection is unavailable currently. EV71 3C mediated the cleavage of many proteins and played an important role in viral inhibiting host innate immunity. Promyelocytic leukemia (PML) protein, the primary organizer of PML nuclear bodies (PML-NBs), can be induced by interferon and is involved in antiviral activity. PML inhibits EV71 replication, and EV71 infection reduces PML expression, but the molecular mechanism is unclear. The cleavage of PMLIII and IV was confirmed by co-transfection of EV71 3C protease and PML. The detailed cleavage sites were evaluated further by constructing the Q to A mutant of PML. PML knockout cells were infected with EV71 to identify the effect of cleavage on EV71 replication. Immunofluorescence analysis to examine the interference of EV71 3C on the formation of PML-NBs. EV71 3C directly cleaved PMLIII and IV. Furthermore, 3C cleaved PMLIV at the sites of Q430-A431 and Q444-S445 through its protease activity. Overexpression of PMLIV Q430A/Q444A variant exhibited stronger antiviral potential than the wild type. PMLIV Q430A/Q444A formed normal nuclear bodies that were not affected by 3C, suggesting that 3C may impair PML-NBs production via PMLIV cleavage and counter its antiviral activities. PML, especially PMLIV, which sequesters viral proteins in PML-NBs and inhibits viral production, is a novel target of EV71 3C cleavage. EV71 3C cleaves PMLIV at Q430-A431 and Q444-S445. Cleavage reduces the antiviral function of PML and decomposes the formation of PML-NBs, which is conducive to virus replication.
Sections du résumé
BACKGROUND
Enterovirus 71 (EV71) usually infects infants causing hand-foot-mouth disease (HFMD), even fatal neurological disease like aseptic meningitis. Effective drug for preventing and treating EV71 infection is unavailable currently. EV71 3C mediated the cleavage of many proteins and played an important role in viral inhibiting host innate immunity. Promyelocytic leukemia (PML) protein, the primary organizer of PML nuclear bodies (PML-NBs), can be induced by interferon and is involved in antiviral activity. PML inhibits EV71 replication, and EV71 infection reduces PML expression, but the molecular mechanism is unclear.
METHODS
The cleavage of PMLIII and IV was confirmed by co-transfection of EV71 3C protease and PML. The detailed cleavage sites were evaluated further by constructing the Q to A mutant of PML. PML knockout cells were infected with EV71 to identify the effect of cleavage on EV71 replication. Immunofluorescence analysis to examine the interference of EV71 3C on the formation of PML-NBs.
RESULTS
EV71 3C directly cleaved PMLIII and IV. Furthermore, 3C cleaved PMLIV at the sites of Q430-A431 and Q444-S445 through its protease activity. Overexpression of PMLIV Q430A/Q444A variant exhibited stronger antiviral potential than the wild type. PMLIV Q430A/Q444A formed normal nuclear bodies that were not affected by 3C, suggesting that 3C may impair PML-NBs production via PMLIV cleavage and counter its antiviral activities. PML, especially PMLIV, which sequesters viral proteins in PML-NBs and inhibits viral production, is a novel target of EV71 3C cleavage.
CONCLUSIONS
EV71 3C cleaves PMLIV at Q430-A431 and Q444-S445. Cleavage reduces the antiviral function of PML and decomposes the formation of PML-NBs, which is conducive to virus replication.
Identifiants
pubmed: 34930370
doi: 10.1186/s12985-021-01725-7
pii: 10.1186/s12985-021-01725-7
pmc: PMC8686290
doi:
Substances chimiques
Promyelocytic Leukemia Protein
0
Peptide Hydrolases
EC 3.4.-
3C Viral Proteases
EC 3.4.22.28
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
255Informations de copyright
© 2021. The Author(s).
Références
Oncogene. 1999 Jan 28;18(4):935-41
pubmed: 10023669
Oncogene. 1991 Jul;6(7):1285-92
pubmed: 1650447
Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16
pubmed: 17928811
Front Immunol. 2018 Jun 05;9:1268
pubmed: 29922292
Annu Rev Biochem. 2017 Jun 20;86:123-128
pubmed: 28654326
J Virol. 2010 Nov;84(22):11634-45
pubmed: 20826694
J Virol. 2016 Jun 10;90(13):5850-5854
pubmed: 27053550
J Virol. 2013 Feb;87(3):1690-8
pubmed: 23175366
J Virol. 2006 Sep;80(17):8582-92
pubmed: 16912307
Front Microbiol. 2015 Jun 18;6:594
pubmed: 26150805
Arch Virol. 1979;60(3-4):329-40
pubmed: 228639
Microbes Infect. 2010 Jul;12(7):505-10
pubmed: 20348010
Autophagy. 2015 Apr 3;11(4):607-16
pubmed: 25906314
PLoS Pathog. 2009 Sep;5(9):e1000593
pubmed: 19779565
Crit Rev Microbiol. 2011 Nov;37(4):313-27
pubmed: 21651436
J Infect Dis. 1974 Mar;129(3):304-9
pubmed: 4361245
J Virol. 2017 Jan 3;91(2):
pubmed: 27847364
J Interferon Cytokine Res. 2011 Jan;31(1):145-58
pubmed: 21198351
Cell Rep. 2015 Jul 7;12(1):42-48
pubmed: 26119741
Curr Microbiol. 2020 Sep;77(9):1968-1975
pubmed: 32556480
J Mol Biol. 2011 May 6;408(3):449-61
pubmed: 21396941
JAMA Neurol. 2016 Mar;73(3):300-7
pubmed: 26785318
Intervirology. 1980;12(6):297-302
pubmed: 6244233
Virology. 2002 Feb 15;293(2):386-95
pubmed: 11886259
J Biomed Sci. 2004 Mar-Apr;11(2):239-48
pubmed: 14966374
Eur J Pediatr. 2016 Aug;175(8):1023-9
pubmed: 27156106
PLoS One. 2012;7(3):e32405
pubmed: 22479324
Viruses. 2016 Mar 17;8(3):82
pubmed: 26999188
Front Oncol. 2013 May 22;3:125
pubmed: 23734343
Virol Sin. 2019 Feb;34(1):9-21
pubmed: 30552635
PLoS One. 2019 Sep 9;14(9):e0221048
pubmed: 31498791
Oncogene. 2001 Oct 29;20(49):7223-33
pubmed: 11704850
J Virol. 2014 Sep 1;88(17):9830-41
pubmed: 24942571
J Virol. 2014 Oct;88(19):11356-68
pubmed: 25056901
N Engl J Med. 1999 Sep 23;341(13):936-42
pubmed: 10498488
Cell. 1991 Aug 23;66(4):675-84
pubmed: 1652369
Annu Rev Biochem. 2017 Jun 20;86:193-224
pubmed: 28460188
Virol Sin. 2021 Feb;36(1):95-103
pubmed: 32696397
PLoS Pathog. 2014 Feb 27;10(2):e1003975
pubmed: 24586174
Cell. 1991 Aug 23;66(4):663-74
pubmed: 1652368
PLoS One. 2012;7(5):e38035
pubmed: 22662263